Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

This expansion reflects LMI's commitment to ensuring broad ... imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...

Preliminary results for trontinemab from 114 participants in the 1.8 or 3.6 mg/kg double-blind period suggest rapid and deep, dose-dependent reduction of amyloid plaques in the brain as measured ...

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Detection is currently tricky. Brain scans like PET can pick up amyloid plaques, the clumps of protein that are the hallmark of the disease, but by the time these form, people’s brain function ...

Please discuss the class and complete drug profile of amyloid-targeting therapies for Alzheimer disease, including their mechanisms of action, efficacy, and safety profiles.

As reported at previous conferences, the antibody managed to remove amyloid plaques quickly while triggering but a ... split equally into four ascending dose groups, then added a dose-expansion study ...

This expansion reflects LMI's commitment to ensuring ... Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation ...